Kelly McCastlain1, Carrie R Howell2, Catherine E Welsh3, Zhaoming Wang4,5, Carmen L Wilson5, Heather L Mulder4, John Easton4, Ann C Mertens6,7, Jinghui Zhang4, Yutaka Yasui5, Melissa M Hudson5, Leslie L Robison5, Mondira Kundu1, Kirsten K Ness5. 1. Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. 2. Department of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Department of Mathematics & Computer Science, Rhodes College, Memphis, TN, USA. 4. Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. 5. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA. 6. Aflac Cancer & Blood Disorders Center at Children's Healthcare of Atlanta, GA, USA. 7. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Abstract
BACKGROUND: Adult childhood cancer survivors are at risk for frailty, including low muscle mass and weakness (sarcopenia). Using peripheral blood mitochondrial DNA copy number (mtDNAcn) as a proxy for functional mitochondria, this study describes cross-sectional associations between mtDNAcn and sarcopenia among survivors. METHODS: Among 1762 adult childhood cancer survivors (51.6% male; median age = 29.4 years, interquartile range [IQR] = 23.3-36.8), with a median of 20.6 years from diagnosis (IQR = 15.2-28.2), mtDNAcn estimates were derived from whole-genome sequencing. A subset was validated by quantitative polymerase chain reaction and evaluated cross-sectionally using multivariable logistic regression for their association with sarcopenia, defined by race-, age-, and sex-specific low lean muscle mass or weak grip strength. All statistical tests were 2-sided. RESULTS: The prevalence of sarcopenia was 27.0%, higher among female than male survivors (31.5% vs 22.9%; P < .001) and associated with age at diagnosis; 51.7% of survivors with sarcopenia were diagnosed ages 4-13 years (P = .01). Sarcopenia was most prevalent (39.0%) among central nervous system tumor survivors. Cranial radiation (odds ratio [OR] = 1.84, 95% confidence interval [CI] = 1.32 to 2.59) and alkylating agents (OR = 1.34, 95% CI = 1.04 to 1.72) increased, whereas glucocorticoids decreased odds (OR = 0.72, 95% CI = 0.56 to 0.93) of sarcopenia. mtDNAcn decreased with age (β = -0.81, P = .002) and was higher among female survivors (β = 9.23, P = .01) and among survivors with a C allele at mt.204 (β = -17.9, P = .02). In adjusted models, every standard deviation decrease in mtDNAcn increased the odds of sarcopenia 20% (OR = 1.20, 95% CI = 1.07 to 1.34). CONCLUSIONS: A growing body of evidence supports peripheral blood mtDNAcn as a biomarker for adverse health outcomes; however, this study is the first to report an association between mtDNAcn and sarcopenia among childhood cancer survivors.
BACKGROUND: Adult childhood cancer survivors are at risk for frailty, including low muscle mass and weakness (sarcopenia). Using peripheral blood mitochondrial DNA copy number (mtDNAcn) as a proxy for functional mitochondria, this study describes cross-sectional associations between mtDNAcn and sarcopenia among survivors. METHODS: Among 1762 adult childhood cancer survivors (51.6% male; median age = 29.4 years, interquartile range [IQR] = 23.3-36.8), with a median of 20.6 years from diagnosis (IQR = 15.2-28.2), mtDNAcn estimates were derived from whole-genome sequencing. A subset was validated by quantitative polymerase chain reaction and evaluated cross-sectionally using multivariable logistic regression for their association with sarcopenia, defined by race-, age-, and sex-specific low lean muscle mass or weak grip strength. All statistical tests were 2-sided. RESULTS: The prevalence of sarcopenia was 27.0%, higher among female than male survivors (31.5% vs 22.9%; P < .001) and associated with age at diagnosis; 51.7% of survivors with sarcopenia were diagnosed ages 4-13 years (P = .01). Sarcopenia was most prevalent (39.0%) among central nervous system tumor survivors. Cranial radiation (odds ratio [OR] = 1.84, 95% confidence interval [CI] = 1.32 to 2.59) and alkylating agents (OR = 1.34, 95% CI = 1.04 to 1.72) increased, whereas glucocorticoids decreased odds (OR = 0.72, 95% CI = 0.56 to 0.93) of sarcopenia. mtDNAcn decreased with age (β = -0.81, P = .002) and was higher among female survivors (β = 9.23, P = .01) and among survivors with a C allele at mt.204 (β = -17.9, P = .02). In adjusted models, every standard deviation decrease in mtDNAcn increased the odds of sarcopenia 20% (OR = 1.20, 95% CI = 1.07 to 1.34). CONCLUSIONS: A growing body of evidence supports peripheral blood mtDNAcn as a biomarker for adverse health outcomes; however, this study is the first to report an association between mtDNAcn and sarcopenia among childhood cancer survivors.
Authors: Ann Z Moore; Mary L Biggs; Amy Matteini; Ashley O'Connor; Sarah McGuire; Brock A Beamer; M Danielle Fallin; Linda P Fried; Jeremy Walston; Aravinda Chakravarti; Dan E Arking Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240
Authors: David J Pagliarini; Sarah E Calvo; Betty Chang; Sunil A Sheth; Scott B Vafai; Shao-En Ong; Geoffrey A Walford; Canny Sugiana; Avihu Boneh; William K Chen; David E Hill; Marc Vidal; James G Evans; David R Thorburn; Steven A Carr; Vamsi K Mootha Journal: Cell Date: 2008-07-11 Impact factor: 41.582
Authors: Xiao Wang; Alicia M Pickrell; Susana G Rossi; Milena Pinto; Lloye M Dillon; Aline Hida; Richard L Rotundo; Carlos T Moraes Journal: Hum Mol Genet Date: 2013-06-10 Impact factor: 6.150
Authors: Kristin L Campbell; Kerri M Winters-Stone; Joachim Wiskemann; Anne M May; Anna L Schwartz; Kerry S Courneya; David S Zucker; Charles E Matthews; Jennifer A Ligibel; Lynn H Gerber; G Stephen Morris; Alpa V Patel; Trisha F Hue; Frank M Perna; Kathryn H Schmitz Journal: Med Sci Sports Exerc Date: 2019-11 Impact factor: 5.411
Authors: Thuy-Tien Dam; Katherine W Peters; Maren Fragala; Peggy M Cawthon; Tamara B Harris; Robert McLean; Michelle Shardell; Dawn E Alley; Anne Kenny; Luigi Ferrucci; Jack Guralnik; Douglas P Kiel; Steve Kritchevsky; Maria T Vassileva; Stephanie Studenski Journal: J Gerontol A Biol Sci Med Sci Date: 2014-05 Impact factor: 6.053
Authors: Thomas N O'Connor; Jacob G Kallenbach; Haley M Orciuoli; Nicole D Paris; John F Bachman; Carl J Johnston; Eric Hernady; Jacqueline P Williams; Robert T Dirksen; Joe V Chakkalakal Journal: Skelet Muscle Date: 2022-04-12 Impact factor: 4.912